IL34

Across TCGA pan-cancer cohorts, IL34 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IL34 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher IL34 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL34 expression acts as an unfavorable survival marker.

BRCA, LIHC, and COAD are the cancer types where IL34 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.599	0.924	<.001	34	view →
LIHC	DFS	Median	All	0.096	0.543	.028	6	view →
COAD	DFS	Median	III,IV	0.019	0.698	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IL34–BRCA (OS)

Open the BRCA breakdown →